WebSify
Follow us on
Mail
Print

Phase III results: tiotropium* Respimat is effective in symptomatic asthma patients irrespective of their allergic status

Source : BUSINESS_WIRE
Last Updated: Mon, Feb 25, 2013 12:30 hrs

San Antonio, Texas, United States:

Tiotropium delivered once daily via Respimat™ significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS†/LABA‡, irrespective of their allergic status.1

Dr. Mark Vandewalker, MD, director, Clinical Research of the Ozarks, Columbia, Missouri (Photo: Business Wire)

These were the main findings from a new subset of data1 from the Phase III UniTinA-asthmaή programme presented for the first time today at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas.

“Patients with asthma may respond differently to treatment based on their allergic status, therefore it is important to investigate new therapies in both allergic and non-allergic patients,” said Dr. Mark Vandewalker, MD, director, Clinical Research of the Ozarks, Columbia, Missouri. “The results of these trials show that tiotropium provides additional bronchodilation and reduces exacerbation rates in asthmatics who are uncontrolled on current therapy with at least ICS/LABA regardless of their allergic status, demonstrating its potential benefit for patients who need additional asthma control.”

The PrimoTinA-asthmaTM studies (1 and 2) were two replicate double-blind parallel-group trials including asthma patients with post-bronchodilator FEV1


blog comments powered by Disqus
most popular on facebook
talking point on sify finance